Tamoxifen (** - Brand names: Nolvadex, Soltamox - Generic: Tamoxifen citrate **)

Other Medications

Description

Tamoxifen is a medication primarily known for its use in treating and preventing breast cancer. It belongs to a class of drugs called selective estrogen receptor modulators (SERMs). In colorectal cancer, tamoxifen has been studied in clinical trials, often in combination with other treatments, to see if it can help prevent the recurrence of cancer or improve outcomes. The clinical trial data available suggests it has been investigated in specific contexts, such as potentially preventing colorectal cancer in patients with breast cancer or in specific patient subgroups, but it is not a standard treatment for colorectal cancer itself. The trial NCT00295646 compared tamoxifen alone or with zoledronate to anastrozole alone or with zoledronate in a large group of patients, primarily focusing on breast cancer but also including colorectal cancer patients.

Mechanism of Action

Tamoxifen works by blocking the effects of estrogen in certain tissues, like breast tissue. It acts as an anti-estrogen in breast cells, preventing estrogen from binding to its receptor and stimulating cancer cell growth. However, it can act as an estrogen agonist (mimicking estrogen) in other tissues, such as the uterus and bone. In the context of colorectal cancer, the potential mechanism involves estrogen's role in tumor growth, although this is not fully established and tamoxifen is not a standard therapy for this disease.

Side Effects

Common side effects of tamoxifen can include hot flashes Vaginal discharge or dryness Mood changes And an increased risk of blood clots (like deep vein thrombosis or pulmonary embolism). Less common but serious side effects can include uterine cancer (endometrial cancer) and cataracts. Because tamoxifen is primarily used for breast cancer The specific side effect profile in colorectal cancer patients might differ or be less well-defined. Patients participating in clinical trials involving tamoxifen would be closely monitored for any adverse effects.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05768139 Phase 1
Recruiting
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
United States, Belgium, France, Germany, Ireland, Italy, Japan, Netherlands, Spa